FCA: Forget Chemoimmunotherapy with Alemtuzumab?

The author presents his views on the efficiency of chemotherapy with alemtuzumab, a monoclonal antibody targeting CD52 protein. He compares the efficiency and mortality caused by alemtuzumab with other monoclonal antibodies such as fludarabine, cyclophosphamide, and rituximab. He comments on the affectivity of the combination of fludarabine with alemtuzumab in chemotherapy.